Compare AbbVie Inc (ABBV) vs ProShares Ultra Semiconductors (USD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbbVie Inc vs ProShares Ultra Semiconductors — how do they compare? AbbVie Inc trades at $253.94 (market cap $449.91B), while ProShares Ultra Semiconductors trades at $88.7. The key difference: AbbVie Inc pays a 2.72% dividend while ProShares Ultra Semiconductors pays none, and AbbVie Inc is trading nearer its 52-week high, ProShares Ultra Semiconductors nearer its low. Which is the better fit depends on your goals.
| ABBV | USD | |
|---|---|---|
Market Cap | $449.91B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $261.07 | $113.53 |
52-Week Low | $184.85 | $37.63 |
Enterprise Value | $513.38B | — |
Dividend Yield | 2.72% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbbVie (ABBV) trades at $254.44, showing slight daily weakness but maintaining a bullish technical structure with strong institutional support. The company has consistently beaten earnings expectations in recent quarters, with Q1 2026 EPS of $2.65 exceeding the $2.59 estimate. Revenue growth is accelerating, reaching $61.16B in 2025, while the immunology portfolio (Skyrizi, Rinvoq) successfully offsets Humira declines. Analyst consensus remains strongly positive with 68% buy ratings and a $266.33 price target.
The outlook is constructive with robust pipeline developments and dividend growth, though elevated valuation multiples (P/E 124.83, P/B 245.29) and looming patent cliffs in the 2030s present risks. Net income margin compression from 20.38% in 2022 to 6.9% in 2025 requires monitoring, but strong cash generation ($19.03B operating cash flow) supports continued shareholder returns.
USD stock trades at $90.36, up 3.26% with a bearish technical signal from moving averages. The company announced a $0.14 dividend payable June 30, 2026. Recent news highlights institutional interest with JPMorgan Chase increasing its stake by 325% in Q3 2026. Technical indicators show neutral oscillators but bearish momentum with key support at $85 and resistance at $93.
The stock faces headwinds from bearish technical momentum despite recent price gains. Institutional accumulation and dividend payments provide support, but the overall technical picture suggests caution. Semiconductor sector volatility remains a key risk factor for this leveraged ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbbVie Inc
AbbVie is a pharmaceutical company with a strong exposure to immunology and oncology. The firm's top drug, Humira, represents close to half of the company's current profits. The company was spun off from Abbott in early 2013. The recent acquisition of Allergan adds several new drugs in aesthetics and women's health.
Read more on ABBV →About ProShares Ultra Semiconductors
USD is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Dow Jones U.S. Semiconductors™ Index. It is a tactical instrument designed for sophisticated traders looking to magnify short-term bullish views on the U.S. semiconductor industry, specifically focusing on large-cap leaders in the chip and equipment space.
Read more on USD →
